ArticleEClinicalMedicine2020
The hepatitis C virus care cascade in the New York City jail system during the direct acting antiviral treatment era, 2014-2017.
Article in EClinicalMedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hepatitis C prevalence in incarcerated settings between 2013-2021: a systematic review and meta-analysis.BMC public health · 2022Pooled it
- Health Benefits, Costs, and Cost-Effectiveness of Jail-Based Hepatitis C Elimination Strategies.JAMA internal medicine · 2026Article
- Hepatitis C treatment in a jail setting: A retrospective cohort analysis of low-barrier initiation of direct acting antivirals.The International journal on drug policy · 2026Observational
- How people die inside: Fact patterns in civil litigation for in-custody deaths.Journal of forensic and legal medicine · 2026Article
- Rationale, design, and methodology of a randomized controlled trial evaluating the impact of peer-enhanced care coordination on linkage to HCV care among formerly incarcerated individuals.Contemporary clinical trials · 2025Article
- MINMON-J: a hybrid implementation pilot study evaluating a low-barrier hepatitis C treatment model in a jail setting.BMJ open · 2025Article
- Prevalence of blood-borne virus infections and uptake of hepatitis C testing and treatment in Australian prisons: the AusHep study.The Lancet regional health. Western Pacific · 2024Article
- Advancing Hepatitis C Elimination through Opt-Out Universal Screening and Treatment in Carceral Settings, United States.Emerging infectious diseases · 2024Review
- Treating Hepatitis C Virus Infection in Jails as an Offset to Declines in Treatment Activity in the Community, New York City, NY, 2014-2020.AJPM focus · 2024Article
- Hepatitis C Cascades: Data to Inform Hepatitis C Elimination in the United States.Public health reports (Washington, D.C. : 1974) · 2023Review
- Access to Hepatitis C Treatment during and after Incarceration in New Jersey, United States: A Qualitative Study.Life (Basel, Switzerland) · 2023Article
- The Hepatitis C Care Cascade During the Direct-Acting Antiviral Era in a United States Commercially Insured Population.Open forum infectious diseases · 2022Article
- The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients.Clinical and molecular hepatology · 2021Article
- Statewide Assessment of the Hepatitis C Virus Care Cascade for Incarcerated Persons in Vermont.Public health reports (Washington, D.C. : 1974)Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundHigh patient turnover presents challenges and opportunity to provide hepatitis C virus (HCV) care in US jails (remand facilities). This study describes the HCV care cascade in the New York City (NYC) jail system during the direct-acting antiviral (DAA) treatment era.
methodsPatients admitted to the NYC jail system from January 2014 through December 2017 were included in this retrospective cohort analysis. We describe rates of screening, diagnosis, linkage to jail-based care, and treatment among the overall cohort, and among subgroups with long jail stays (≥120 days) or frequent stays (≥10 admissions). The study protocol was approved by a third-party institutional review board (BRANY, Lake Success, NY).
findingsAmong the 121,371 patients in our analysis, HCV screening was performed in 40,219 (33%), 4665 (12%) of whom were viremic, 1813 (39%) seen by an HCV clinician in jail, and 248 (5% of viremic patients) started on treatment in jail. Having a long stay (adjusted risk ratio [aRR] 8·11, 95% confidence interval [CI] 6·98, 9·42) or frequent stays (aRR 1·51, 95% CI 1·04, 2·18) were significantly associated with being seen by an HCV clinician. Patients with long stays had a higher rate of treatment (14% of viremic patients). Sustained virologic response at 12 weeks was achieved in 147/164 (90%) of patients with available virologic data.
interpretationJail health systems can reach large numbers of HCV-infected individuals. The high burden of HCV argues for universal screening in jail settings. Length of stay was strongly associated with being seen by an HCV clinician in jail. Treatment is feasible among those with longer lengths of stay.
fundingNone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.